GILEAD SCIENCES, INC. bought KYTX
February 12, 2024 · Form 4 insider transaction
GILEAD SCIENCES, INC. bought 3,216,119 shares of Kyverna Therapeutics, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Acquired (buy-side)
Shares
3,216,119
Price
N/A
Total value
N/A
InsiderGILEAD SCIENCES, INC.
Role—
SecurityCommon Stock
Transaction codeC: Conversion of a derivative
Transaction dateFebruary 12, 2024
Filing dateFebruary 13, 2024
Shares owned after3,216,119
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date.; Reflects a 1-for-4.5511 reverse stock split, which became effective on January 30, 2024.